Sacituzumab Tirumotecan for Pancreatic Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Sacituzumab tirumotecan
Related studies linked through entity extraction aliases.
A Phase II Study of Sacituzumab Tirumotecan in Combination With Furmonertinib in Patients With Non-squamous Non-Small Cell Lung Cancer Who Have Progressed After EGFR-TKI and Platinum-Based Chemotherapy
- Status
- RECRUITING
- Phase
- PHASE2
Sacituzumab Tirumotecan in Recurrent/Metastatic Adenoid Cystic Carcinoma and Papillary Thyroid Carcinoma (STRAP)
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Phase 2 Trial Of Sacituzumab Tirumotecan For Treatment Of Refractory Metastatic Or Unresectable Squamous Cell Carcinoma Of The Anus/Rectum
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Sac-TMT for Active TNBC Brain Metastases
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Phase II Trial of Sacituzumab Tirumotecan in Patients With SMARCB1-Deficient Renal Medullary Carcinoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
- Status
- RECRUITING
- Phase
- PHASE3
Sacituzumab Tirumotecan Plus Anlotinib in Previously Treated ES-SCLC
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Single-Arm, Phase II Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan in Second-Line and Subsequent Treatments for Advanced Thymic Epithelial Tumors
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib or Sacituzumab Tirumotecan for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Sacituzumab Tirumotecan in Participants With Locally Advanced or Metastatic Thymic Carcinoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
- Status
- RECRUITING
- Phase
- PHASE3
A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Sac-TMT Combined With Toripalimab for First-line Treatment of PD-L1 Positive a/mTNBC
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
- Status
- RECRUITING
- Phase
- PHASE3
Sacituzumab Tirumotecan in Combination With Furmonertinib as Second-line Treatment for EGFR-mutant Advanced or Metastatic NSCLC After Failure of First-line Third-generation EGFR-TKI Therapy
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Sacituzumab Tirumotecan in Combination With Tagitanlimab in the Treatment of Aggressive Variant Prostate Cancer (AVPC) and Neuroendocrine Prostate Cancer (NEPC)
- Status
- RECRUITING
- Phase
- PHASE2
SKB264 Combined With KL-A167 Neoadjuvant Therapy for Early-stage, High-risk ER+/HER2- Breast Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Sacituzumab Tirumotecan in Neoadjuvant Treatment of Early-Stage TNBC
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2